$DCTH
Delcath Systems Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021026362 Filed on May 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1 2019 Q4
Revenue $390.0K $290.0K $520.0K
YoY Change 34.48% 7.41% -49.02%
Cost Of Revenue $110.0K $78.00K $280.0K
YoY Change 41.03% -18.75% -31.71%
Gross Profit $280.0K $216.0K $240.0K
YoY Change 29.63% 24.14% -60.66%
Gross Profit Margin 71.79% 74.48% 46.15%
Selling, General & Admin $3.300M $2.316M $2.080M
YoY Change 42.49% -9.14% -17.79%
% of Gross Profit 1178.57% 1072.22% 866.67%
Research & Development $3.710M $2.974M $2.700M
YoY Change 24.75% -9.88% -53.13%
% of Gross Profit 1325.0% 1376.85% 1125.0%
Depreciation & Amortization $40.00K $50.00K $40.00K
YoY Change -20.0% -23.08% -60.0%
% of Gross Profit 14.29% 23.15% 16.67%
Operating Expenses $7.010M $5.290M $4.780M
YoY Change 32.51% 107.53% -42.41%
Operating Profit -$6.730M -$5.074M -$4.540M
YoY Change 32.64% 113.64% -40.96%
Interest Expense -$40.00K -$56.00K $17.03M
YoY Change -28.57% -97.49% -622.39%
% of Operating Profit
Other Income/Expense, Net $20.00K $80.00K $0.00
YoY Change -75.0% 3900.0% -100.0%
Pretax Income -$6.750M -$7.860M $12.49M
YoY Change -14.12% -0.38% -214.9%
Income Tax
% Of Pretax Income
Net Earnings -$6.747M -$7.861M $12.49M
YoY Change -14.17% -0.42% -214.9%
Net Earnings / Revenue -1730.0% -2710.69% 2401.92%
Basic Earnings Per Share -$108.10
Diluted Earnings Per Share -$1.038M -$112.3M $416.3M
COMMON SHARES
Basic Shares Outstanding 72.77K 21.98M
Diluted Shares Outstanding 72.74K

Balance Sheet

Concept 2021 Q1 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.60M $4.540M $10.00M
YoY Change 485.9% 1646.15% 296.83%
Cash & Equivalents $26.65M $4.721M $10.00M
Short-Term Investments
Other Short-Term Assets $2.420M $2.820M $1.940M
YoY Change -14.18% 36.89% 40.58%
Inventory $1.110M $790.0K $654.0K
Prepaid Expenses
Receivables $80.00K $70.00K $21.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $30.20M $8.220M $12.62M
YoY Change 267.4% 159.63% 113.16%
LONG-TERM ASSETS
Property, Plant & Equipment $2.110M $1.560M $735.0K
YoY Change 35.26% -48.0% -20.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $2.120M $1.560M $1.595M
YoY Change 35.9% -47.9% 72.43%
TOTAL ASSETS
Total Short-Term Assets $30.20M $8.220M $12.62M
Total Long-Term Assets $2.120M $1.560M $1.595M
Total Assets $32.32M $9.780M $14.21M
YoY Change 230.47% 58.77% 107.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.230M $5.000M $4.533M
YoY Change -75.4% -51.31% -41.24%
Accrued Expenses $6.360M $8.050M $6.947M
YoY Change -20.99% -14.18% -12.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $2.000M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $10.10M $13.04M $15.99M
YoY Change -22.55% -48.74% -9.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.000M $2.000M
YoY Change -100.0%
Other Long-Term Liabilities $2.210M $2.740M $0.00
YoY Change -19.34% 1550.6% -100.0%
Total Long-Term Liabilities $2.210M $4.740M $0.00
YoY Change -53.38% 2755.42% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.10M $13.04M $15.99M
Total Long-Term Liabilities $2.210M $4.740M $0.00
Total Liabilities $12.31M $17.78M $20.57M
YoY Change -30.76% -40.62% -5.57%
SHAREHOLDERS EQUITY
Retained Earnings -$371.2M
YoY Change 7.88%
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.01M -$8.005M -$6.357M
YoY Change
Total Liabilities & Shareholders Equity $32.32M $9.780M $14.21M
YoY Change 230.47% 58.77% 107.66%

Cashflow Statement

Concept 2021 Q1 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income -$6.747M -$7.861M $12.49M
YoY Change -14.17% -0.42% -214.9%
Depreciation, Depletion And Amortization $40.00K $50.00K $40.00K
YoY Change -20.0% -23.08% -60.0%
Cash From Operating Activities -$4.567M -$5.229M -$5.370M
YoY Change -12.66% 88.77% 191.85%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $180.0K -$20.00K
YoY Change -105.56% 8900.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.000K -$180.0K -$20.00K
YoY Change -95.0% 8900.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.376M -117.0K -20.00K
YoY Change -2130.77% -121.27% -99.53%
NET CHANGE
Cash From Operating Activities -4.567M -5.229M -5.370M
Cash From Investing Activities -9.000K -180.0K -20.00K
Cash From Financing Activities 2.376M -117.0K -20.00K
Net Change In Cash -2.106M -5.462M -5.410M
YoY Change -61.44% 142.54% -11.89%
FREE CASH FLOW
Cash From Operating Activities -$4.567M -$5.229M -$5.370M
Capital Expenditures -$10.00K $180.0K -$20.00K
Free Cash Flow -$4.557M -$5.409M -$5.350M
YoY Change -15.75% 95.13% 193.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
20631
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
20631
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5996101
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5996101
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10035000
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
450000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2072000
CY2020Q1 us-gaap Gross Profit
GrossProfit
216000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2974000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5290000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2316000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
94000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6357000
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
30000
CY2020Q1 dcth Adjustment To Additional Paid In Capital Registration Of Preferred Stock And Related Warrants
AdjustmentToAdditionalPaidInCapitalRegistrationOfPreferredStockAndRelatedWarrants
106000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6199000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
65000
CY2020Q1 dcth Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
11000
CY2021Q1 dcth Interest Income Earned On Money Market And Operating Accounts
InterestIncomeEarnedOnMoneyMarketAndOperatingAccounts
1000
CY2021Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
39000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2148000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
57000
CY2021Q1 dcth Stock Issued During Period Value Exchange Of Warrants For Common Stock
StockIssuedDuringPeriodValueExchangeOfWarrantsForCommonStock
2376000
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
40000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-239000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-188000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4567000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5229000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-180000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
11000
CY2020Q1 dcth Payments Related To Registration Costs
PaymentsRelatedToRegistrationCosts
106000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2376000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2376000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-117000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94000
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2106000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5462000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10183000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26650000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4721000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
3000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
4000
CY2020Q1 dcth Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
6199000
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Reclassifications<font style="font-style:normal;">. Certain prior period balances have been reclassified in order to conform to current period presentation. These reclassifications have no effect on previously reported results of operations or loss per share.</font></p>
CY2020Q4 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2021Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
486000
CY2020Q4 dcth Letters Of Credit Restricted Cash
LettersOfCreditRestrictedCash
131000
CY2021Q1 dcth Security For Credit Cards Restricted Cash
SecurityForCreditCardsRestrictedCash
50000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
435000
CY2021Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
623000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
420000
CY2021Q1 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1497000
CY2020Q4 dcth Prepaid Clinical Trial Expenses Current
PrepaidClinicalTrialExpensesCurrent
1497000
CY2021Q1 us-gaap Prepaid Insurance
PrepaidInsurance
498000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
845000
CY2021Q1 dcth Prepaid Professional Service Fees
PrepaidProfessionalServiceFees
125000
CY2020Q4 dcth Prepaid Professional Service Fees
PrepaidProfessionalServiceFees
66000
CY2021Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
249000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
262000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6054000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6064000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4733000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4713000
CY2020Q3 dcth Exercised Option To Purchase
ExercisedOptionToPurchase
460300
CY2021Q1 dcth Property Plant And Equipment Depreciation Expense
PropertyPlantAndEquipmentDepreciationExpense
38800
CY2020Q1 dcth Property Plant And Equipment Depreciation Expense
PropertyPlantAndEquipmentDepreciationExpense
47600
CY2021Q1 dcth Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
3511000
CY2020Q4 dcth Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
2698000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
335000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
274000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
234000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
486000
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
169000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
44000
CY2021Q1 us-gaap Lease Cost
LeaseCost
125000
CY2021Q1 us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
44000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
377000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
406000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
67000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
850000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
60000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
790000
CY2021Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2021-07-16
CY2021Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
15000
CY2021Q1 dcth Stock Issued During Period Shares Associated With Warrants
StockIssuedDuringPeriodSharesAssociatedWithWarrants
237520
CY2021Q1 dcth Issue Of Unregistered Common Stock For Advisory Services
IssueOfUnregisteredCommonStockForAdvisoryServices
2636
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1078499
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1078499
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
175164
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.68
CY2020Q4 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
9.13
CY2021Q1 dcth Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period
ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
10.00
CY2021Q1 dcth Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
9.07
CY2021Q1 dcth Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
9.07
CY2021Q1 dcth Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P3Y10M24D
CY2021Q1 dcth Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm
P3Y10M24D
CY2021Q1 dcth Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
13372000
CY2021Q1 dcth Class Of Warrant Or Right Exercisable Intrinsic Value
ClassOfWarrantOrRightExercisableIntrinsicValue
13372000
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
CY2020Q1 dcth Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Fair Value Of Warrants Reclassified From Liability To Equity
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisFairValueOfWarrantsReclassifiedFromLiabilityToEquity
6199000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7266995
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3690825
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.68
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.05
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y6M
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
710000
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
131000
CY2021Q1 dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
2148000
CY2020Q1 dcth Share Based Compensation Income Expense
ShareBasedCompensationIncomeExpense
55000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6677000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4236687
CY2021Q1 dcth Class Of Warrant Or Right Exercises In Period
ClassOfWarrantOrRightExercisesInPeriod
242580
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3994107
CY2021Q1 dcth Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
3994107
CY2021Q1 dcth Number Of Shares Pre Funded Penny Warrants Outstanding
NumberOfSharesPreFundedPennyWarrantsOutstanding
371000
CY2021Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6125922
CY2020Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
72740
CY2021Q1 dcth Weighted Average Number Of Shares Pre Funded Warrants1
WeightedAverageNumberOfSharesPreFundedWarrants1
371000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6496922
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72740

Files In Submission

Name View Source Status
0001564590-21-026362-index-headers.html Edgar Link pending
0001564590-21-026362-index.html Edgar Link pending
0001564590-21-026362.txt Edgar Link pending
0001564590-21-026362-xbrl.zip Edgar Link pending
dcth-10q_20210331.htm Edgar Link pending
dcth-20210331.xml Edgar Link completed
dcth-20210331.xsd Edgar Link pending
dcth-20210331_cal.xml Edgar Link unprocessable
dcth-20210331_def.xml Edgar Link unprocessable
dcth-20210331_lab.xml Edgar Link unprocessable
dcth-20210331_pre.xml Edgar Link unprocessable
dcth-ex311_10.htm Edgar Link pending
dcth-ex312_7.htm Edgar Link pending
dcth-ex321_8.htm Edgar Link pending
dcth-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending